{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.2"},{"groupId":"OG001","value":"63.9"}]}],"title":"Chemotherapy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.3"},{"groupId":"OG001","value":"48.5"}]}],"title":"Radiotherapy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5"},{"groupId":"OG001","value":"50.4"}]}],"title":"Hormone Therapy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1864"},{"groupId":"OG001","value":"709"}],"units":"Participants"}],"description":"Concomitant cancer treatment included chemotherapy, radiotherapy, and hormone therapy administered during the study. The percentage of participants who received any of these concomitant therapies was reported.","groups":[{"description":"Participants received SC Herceptin by an assisted administration as 600 mg every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was taken from a single-use vial and injected by needle/syringe.","id":"OG000","title":"Cohort A: SC Herceptin by Needle/Syringe"},{"description":"Participants received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was administered from a pre-filled SID. The first administration was performed by an HCP. Subsequent doses were self-administered by participants who were willing and judged competent by the HCP.","id":"OG001","title":"Cohort B: SC Herceptin by SID"}],"paramType":"NUMBER","populationDescription":"Safety Population","reportingStatus":"POSTED","timeFrame":"From Baseline to data cutoff of 10 March 2015 (up to approximately 3 years)","title":"Percentage of Participants Who Received Concomitant Cancer Therapy","type":"PRIMARY","unitOfMeasure":"percentage of participants"}